Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research.
Prasinezumab against an epitope in the carboxyl terminus of human α-synuclein. Prasinezumab binds to human aggregated α-synuclein with a high affinity and avidity[1].
References:
[1]. Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407.